We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

64 hedge funds and large institutions have $32.8M invested in Akoya BioSciences in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,400% more call options, than puts

Call options by funds: $75K | Put options by funds: $1K

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

18% more capital invested

Capital invested by funds: $27.8M → $32.8M (+$5.05M)

5% more funds holding

Funds holding: 6164 (+3)

0.75% more ownership

Funds ownership: 24.49%25.24% (+0.75%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 19

Holders
64
Holders Change
+3
Holders Change %
+4.92%
% of All Funds
0.86%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
10
Increased
19
Reduced
19
Closed
7
Calls
$75K
Puts
$1K
Net Calls
+$74K
Net Calls Change
-$45K
Name Holding Trade Value Shares
Change
Change in
Stake
N
1
Nuveen
North Carolina
$15.9M +$771K +352,356 +863%
BWLSA
2
Blue Water Life Science Advisors
California
$6.53M
BlackRock
3
BlackRock
New York
$2.24M -$55.5K -25,328 -2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.93M -$41.3K -18,862 -1%
PAPAIJV
5
Paragon Associates & Paragon Associates II Joint Venture
Texas
$933K -$285K -130,000 -16%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$788K +$3.27K +1,493 +0.3%
State Street
7
State Street
Massachusetts
$686K +$127K +57,960 +13%
JP Morgan Chase
8
JP Morgan Chase
New York
$572K +$795K +363,298 +752%
UBS Group
9
UBS Group
Switzerland
$392K +$431K +196,788 +231%
PCA
10
Peddock Capital Advisors
Massachusetts
$326K
Northern Trust
11
Northern Trust
Illinois
$321K -$41.9K -19,123 -8%
CIEC
12
Crédit Industriel et Commercial
France
$236K +$372K +170,000 New
Verition Fund Management
13
Verition Fund Management
Connecticut
$231K +$364K +166,314 New
Morgan Stanley
14
Morgan Stanley
New York
$158K -$35.2K -16,071 -12%
Millennium Management
15
Millennium Management
New York
$157K +$248K +113,245 New
VF
16
Virtu Financial
New York
$142K +$223K +101,993 New
Goldman Sachs
17
Goldman Sachs
New York
$139K +$42.6K +19,475 +24%
RhumbLine Advisers
18
RhumbLine Advisers
Massachusetts
$103K +$92.4K +42,204 +132%
Charles Schwab
19
Charles Schwab
California
$87.6K +$53 +24 +0%
Deutsche Bank
20
Deutsche Bank
Germany
$76.2K
Squarepoint
21
Squarepoint
New York
$72.5K +$114K +52,159 New
ZIC
22
ZWJ Investment Counsel
Georgia
$66.7K +$5.91K +2,700 +6%
AI
23
Atom Investors
Texas
$65.5K +$103K +47,087 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$62.9K -$11.9K -5,445 -11%
Invesco
25
Invesco
Georgia
$62.7K +$98.8K +45,141 New

AKYA Hedge Fund Activity: Q1 2025 in Review

64 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q1 2025, worth a combined $32.8M — up 18% from $27.8M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new AKYA positions and 7 closed out — a net gain of 3 holders — while 19 added to existing stakes and 19 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $795K. The largest seller was SVB Wealth, cutting an estimated $1.13M.

  • 64 institutional investors held Akoya BioSciences (AKYA) as of Q1 2025, up from 61 in Q4 2024.
  • Funds reported $32.8M of Akoya BioSciences stock for Q1 2025, up 18% quarter-over-quarter.
  • 10 funds opened new Akoya BioSciences positions in Q1 2025 and 7 closed out, a net change of +3 holders.
  • The largest Akoya BioSciences buyer in Q1 2025 was JP Morgan Chase, an estimated $795K added.
  • The largest Akoya BioSciences seller in Q1 2025 was SVB Wealth, an estimated $1.13M sold.

Based on aggregated 13F filings for Q1 2025.